Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Drug Analysis: V180 - More Compact Dosing Schedule Could Make It a More Attractive Alternative to Dengvaxia -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: V180" drug pipelines has been added to's offering.

Merck & Co's adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241). The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are then formulated with either ISCOMATRIX (saponin, cholesterol, and phospholipid adjuvant; CSL) or Alhydrogel (aluminium hydroxide gel adjuvant; Brenntag Nordic).

V180 is currently in Phase I development in the US and Australia only, but Merck & Co is likely to target the same dengue-endemic Asia-Pacific and Latin American markets as Sanofi Pasteur and Takeda.

V180's more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers, although its current three-dose schedule could still be improved upon to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV (tetravalent live-attenuated chimeric vaccine; Biological E/Panacea Biotec/Butantan Institute/Merck & Co/Vabiotech), which the company has in-licensed from the US National Institutes of Health, potentially simplifying the vaccination schedule to just two doses. Such a strategy would be attractive for routine immunization programs and for the traveler/military segments, but V180 will likely face competition from GlaxoSmithKline, which is currently pursuing a similar strategy with DPIV (adjuvanted, tetravalent formalin-inactivated vaccine). However, Merck & Co is yet to launch Phase II trials, and since there has been no progress in development since Q4 2016, the future of V180 is unclear.

Key Topics Covered:

Product Profiles

V180: Dengue vaccines

List of Figures

Figure 1: V180 for dengue fever - SWOT analysis

List of Tables

Table 1: V180 drug profile

Table 2: V180 Phase I data in dengue fever

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.